We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
David Rosenbaum, Chief Debriefing Officer, Ardelyx, said: "Tenapanor will be the first non-phosphate-binding agent to treat hyperphosphatemia in dialysis patients with ESRD if approved.